Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

Blood cancer journal·2026

Same author

Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.

British journal of haematology·2026

Same author

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Blood advances·2026

Same author

Epidemiology of Erdheim-Chester disease in the United States: a SEER-based analysis.

Blood neoplasia·2026

Same author

A Masked Intruder: Extranodal Natural Killer/T-Cell Lymphoma Mimicking Preseptal Cellulitis.

Mayo Clinic proceedings. Innovations, quality & outcomes·2026

Same author

The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphoma.

Blood cancer journal·2025

Search research articles

Related Experiment Video

Updated: Jan 31, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Tumor Microenvironment in T-Cell Lymphomas.

N Nora Bennani¹, Stephen M Ansell²

¹Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Cancer Treatment and Research

|January 1, 2019

Summary

T-cell lymphomas (TCL) are aggressive cancers with poor outcomes. Understanding the tumor microenvironment and immune cell roles may lead to new therapies, potentially combining immune checkpoint blockade and CD47-SIRPalpha axis modulation.

Keywords:

CD47-SIRPalpha axis Checkpoint blockade Helper T-cells Immunotherapy Regulatory T-cells T-cell lymphoma Tumor microenvironment

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Related Experiment Videos

Last Updated: Jan 31, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Area of Science:

Oncology
Immunology
Hematology

Background:

T-cell lymphomas (TCL) are rare, aggressive non-Hodgkin lymphomas with limited treatment options and poor prognosis, especially upon relapse.
The tumor microenvironment plays a critical role in tumor evasion and T-cell dysfunction, despite inflammatory responses.

Purpose of the Study:

To explore novel therapeutic strategies for T-cell lymphomas by investigating the role of nonmalignant immune cells within the tumor microenvironment.
To identify potential targets for enhancing antitumor immune responses in T-cell lymphomas.

Main Methods:

Investigating immune checkpoint blockade to reinvigorate suppressed T-cells.
Exploring modulation of the CD47-SIRPalpha axis to enhance macrophage phagocytosis.
Evaluating the potential for combination therapy targeting these immune pathways.

Main Results:

The tumor microenvironment contributes to ineffective T-cell responses in T-cell lymphomas.
Immune modulation strategies, including immune checkpoint blockade and CD47-SIRPalpha axis targeting, show promise.
The necessity of single-agent versus combination therapy requires further investigation.

Conclusions:

A deeper understanding of the tumor microenvironment is crucial for developing effective treatments for T-cell lymphomas.
Targeting immune pathways offers potential for improved therapeutic outcomes in these hematologic malignancies.
Further research is needed to determine optimal therapeutic combinations for T-cell lymphoma treatment.